Press Releases

“[...] large multicenter prospective randomized trials are needed to provide the clinical evidence for the use of [chemotherapy] in second line and third-line post [immunotherapy] failure.”

BUFFALO, NY- June 7, 2023 – A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, “Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC).”

Lung cancer is the number one cause of mortality among all types of cancer worldwide. Its... continue reading >>

“The current study analyzed the correlation between BORIS mutations and the expression of the protein in breast cancer cases.”

BUFFALO, NY- June 5, 2023 – A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, “Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression.”

The brother of the regulator of imprinted sites (BORIS), 11 zinc-finger transcription factors, is a member of the... continue reading >>

“In this study, we present novel transcriptional dependencies between MALAT1 and MAPK-pathway-associated genes in melanoma.”

BUFFALO, NY- May 30, 2023 – A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, “Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment.”

The long non-coding RNA (lncRNA) MALAT1 is a regulator of oncogenesis and cancer progression. MAPK-pathway upregulation is the main... continue reading >>

“[...] we discovered that the surrounding liver EC microenvironment plays a key role in activating HER3 and promoting cell survival in mCRC and mPDAC [...].”

BUFFALO, NY- May 24, 2023 – A new research perspective was published in Oncotarget's Volume 14 on May 10, 2023, entitled, “HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma.”

Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) are highly... continue reading >>

“This research uncovers GPR141 as a stimulator of breast tumorigenesis and metastasis, making it a candidate target for breast cancer therapeutics.”

BUFFALO, NY- May 22, 2023 – A new research paper was published in Oncotarget's Volume 14 on May 19, 2023, entitled, “G-protein-coupled receptor 141 mediates breast cancer proliferation and metastasis by regulating oncogenic mediators and the p-mTOR/p53 axis.”

Breast cancer morbidity is surging towards the peak in females across the globe. An... continue reading >>

“Here, we provide a brief overview of the status quo of targeting mitochondrial energy metabolism in glioblastoma and highlight a novel combination therapy.”

BUFFALO, NY- May 19, 2023 – A new research perspective was published in Oncotarget's Volume 14 on May 4, 2023, entitled, “Targeting cellular respiration as a therapeutic strategy in glioblastoma.”

While glycolysis is abundant in malignancies, mitochondrial metabolism is significant as well. Mitochondria harbor the enzymes relevant for... continue reading >>

Impact Journals (Oncotarget's publisher) is proud to participate at the Society for Scholarly Publishing (SSP) 45th Annual Meeting, which convenes May 31–June 2, 2023, in Portland, Oregon.

BUFFALO, NY-May 17, 2023 – Impact Journals (Oncotarget's publisher) will be participating as an exhibitor at the Society for Scholarly Publishing (SSP) 45th Annual Meeting, which convenes on May 31–June 2, 2023, at the Oregon Convention Center & Hyatt Regency Portland in Portland, Oregon, USA. This year, the... continue reading >>

“[...] we have developed a fully automated calling algorithm for determining B and T cell clonality from NGS [next-generation sequencing] data, with greater sensitivity than previously developed models.”

BUFFALO, NY- May 16, 2023 – A new research paper was published in Oncotarget's Volume 14 on May 12, 2023, entitled, “Development and implementation of an automated and highly accurate reporting process for NGS-based clonality testing.”

B and T cells undergo random recombination of the... continue reading >>

“[...] we consider some public molecular resources, including proteomics datasets, that may be leveraged to help identify gene candidates for therapeutic targeting in cancer.”

BUFFALO, NY- May 10, 2023 – A new research perspective was published in Oncotarget's Volume 14 on May 4, 2023, entitled, “Using cancer proteomics data to identify gene candidates for therapeutic targeting.”

Gene-level associations obtained from mass-spectrometry-based cancer proteomics datasets represent a resource... continue reading >>

“Importantly, the expression of several LY6 genes is elevated in UCEC [uterine corpus endometrial carcinoma] when compared to the expression in normal uterine tissue.”

BUFFALO, NY- May 8, 2023 – A new research paper was published in Oncotarget's Volume 14 on May 4, 2023, entitled, “Human LY6 gene family: potential tumor-associated antigens and biomarkers of prognosis in uterine corpus endometrial carcinoma.”

The human Lymphocyte antigen-6 (LY6) gene family has recently gained interest for... continue reading >>

“AL amyloidosis is a fatal disease and systemic therapy is required to prevent deposition of amyloid in other organs and prevent progressive organ failure.”

BUFFALO, NY- May 5, 2023 – A new review paper was published in Oncotarget's Volume 14 on April 26, 2023, entitled, “Systemic AL amyloidosis: current approach and future direction.”

In this review, researchers Maroun Bou Zerdan, Lewis Nasr, Farhan Khalid, Sabine Allam, Youssef Bouferraa, Saba Batool, Muhammad Tayyeb, Shubham Adroja,... continue reading >>

“Retinoids are known to inhibit tumor-promoting IL-6 production.”

BUFFALO, NY- May 3, 2023 – A new research perspective was published in Oncotarget's Volume 14 on April 26, 2023, entitled, “Disruption of retinol-mediated IL-6 expression in colon cancer-associated fibroblasts: new perspectives on the role of vitamin A metabolism.”

Colon cancer (CRC) is one of the most common malignancies and is a leading cause of cancer-related deaths worldwide. While the tumor microenvironment (TME)... continue reading >>

“A biomarker or set of biomarkers to inform on the individual progression risk would be beneficial to the patient and cost-effective for the healthcare system.”

BUFFALO, NY- May 2, 2023 – A new research perspective was published in Oncotarget's Volume 14 on April 24, 2023, entitled, “Crossroads: the role of biomarkers in the management of lumps in the breast.”

Here, Dr. Georg F. Weber from the University of Cincinnati Academic Health Center discusses a long-standing issue in women’s health: ... continue reading >>

“Our study emphasizes the importance of distinguishing between STAT3α and STAT3β proteins and their active forms when discussing STAT3-related cancer diagnosis and therapy.”

BUFFALO, NY- April 26, 2023 – A new research paper was published in Oncotarget's Volume 14 on April 24, 2023, entitled, “Differential silencing of STAT3 isoforms leads to changes in STAT3 activation.”

Signal transducer and activator of transcription 3 (STAT3) is a transcription factor involved in multiple fundamental... continue reading >>

“[...] we found that blocking necroptosis leads to the inhibition of metastasis in mouse breast cancer models [...]”

BUFFALO, NY- April 24, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on April 10, 2023, entitled, “Tumor necroptosis promotes metastasis through modulating the interplay between tumor and host immunity.”

In this new editorial, researchers Zhaoshan Liu, Swati Choksi and Zheng-Gang Liu from the National Institutes of Health’s National Cancer Institute... continue reading >>

“To our knowledge, there are no studies evaluating the prognostic importance of CEA and Ca 19-9 in patients with DA [duodenal adenocarcinoma].”

BUFFALO, NY- April 18, 2023 – A new research paper was published in Oncotarget's Volume 14 on April 15, 2023, entitled, “Importance of carbohydrate antigen (CA 19-9) and carcinoembrionic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study.”

Duodenal adenocarcinoma (DA) is a rare... continue reading >>

“[...] long-term treatment with rapamycin slows down aging, a major risk factor for cancer [...]”

BUFFALO, NY- April 17, 2023 – A new research perspective was published in Oncotarget's Volume 14 on April 14, 2023, entitled, “Cancer prevention with rapamycin.”

The mTOR (Target of Rapamycin) pathway is involved in both cancer and aging. Furthermore, common cancers are age-related diseases, and their incidence increases exponentially with age. In his new research perspective, Mikhail V.... continue reading >>

“Our phase I study determined the tolerable dose of this combination and investigated its biologic effects.” 

BUFFALO, NY- April 12, 2023 – A new research paper was published in Oncotarget's Volume 14 on April 10, 2023, entitled, “A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.”

Overexpression of metabotropic glutamate receptor 1 (GRM1) has been implicated in the pathogenesis of multiple cancers. Riluzole, an inhibitor of glutamate release,... continue reading >>

“[...] the study of immunotherapy for treating triple negative breast cancer might still be at its early stages of development but is full of future promise.” 

BUFFALO, NY- April 10, 2023 – A new review paper was published in Oncotarget's Volume 14 on March 31, 2023, entitled, "Crosstalk between triple negative breast cancer and microenvironment."

Although many advances have been made in the treatment of breast cancer, for triple negative breast cancer (TNBC) these therapies have not... continue reading >>

“Beyond detection of cancer, CAFs are being actively pursued as targets for therapy.” 

BUFFALO, NY- April 5, 2023 – A new editorial perspective was published in Oncotarget's Volume 14 on March 21, 2023, entitled, “Cancer-associated fibroblasts: challenges and opportunities.”

Cancer-associated fibroblasts (CAFs) are a type of cell that plays a key role in the tumor microenvironment. While these cells have been extensively studied, their precise role in cancer development and progression... continue reading >>

Impact Journals (Oncotarget's publisher) is proud to participate at the American Association for Cancer Research (AACR) Annual Meeting 2023, which convenes April 14-19 in Orlando, Florida.

BUFFALO, NY-April 4, 2023 – Impact Journals will be participating as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2023 from April 14-19 at the Orange County Convention Center in Orlando, Florida. This year, the AACR meeting theme is: “Advancing the Frontiers of Cancer... continue reading >>

“Cortactin (also known as EMS1 or CTTN) is expressed broadly in a variety of cancers [...]” 

BUFFALO, NY- April 4, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on March 21, 2023, entitled, “Impact of cortactin in cancer progression on Wnt5a/ROR1 signaling pathway.”

In this editorial, researchers Kamrul Hasan and Thomas J. Kipps from the University of California discuss cortactin—an intracellular cytoskeletal protein that can undergo tyrosine phosphorylation upon... continue reading >>

“In the present study, we found that downregulation of angulin-1/LSR induced malignancy via upregulation of EGF-dependent CLDN-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma.” 

BUFFALO, NY- March 29, 2023 – A new research paper was published in Oncotarget's Volume 14 on March 24, 2023, entitled, “Downregulation of angulin-1/LSR induces malignancy via upregulation of EGF-dependent claudin-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma A549 cells.”

Abnormal... continue reading >>

"[...] mutations in G-proteins have been associated in the progress of several cancers [...]”

BUFFALO, NY- March 28, 2023 – A new research paper was published in Oncotarget's Volume 14 on March 24, 2023, entitled, “Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines.”

Finding effective therapies against cancers driven by mutant and/or overexpressed hyperactive G-proteins remains an area of active research.... continue reading >>

“This study was designed to increase the knowledge on the potential of GPCs and in particular GPC1 as a biomarker in cancer diagnosis and prognosis.” 

BUFFALO, NY- March 22, 2023 – A new research paper was published in Oncotarget's Volume 14 on March 21, 2023, entitled, “Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior.”

Glypicans (GPC1-6) are associated with tumorigenic processes and their involvement in neoplastic behavior... continue reading >>

“We are very enthusiastic about these initiatives and the recent rate of discoveries in OSA, and hopeful that they will bring actionable targets for OSA.” 

BUFFALO, NY- March 20, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on February 11, 2023, entitled, “Unlocking the potential of molecular-driven stratification for osteosarcoma treatment and prognosis.”

Over the last 40 years, the complex genetic landscape, the heterogeneity of the microenvironment and the cell... continue reading >>

“In breast cancer, MTAP downregulation activates ornithine decarboxylase (ODC) which in turn leads to formation of putrescine which promotes tumor migration, invasion and angiogenesis [15].”

BUFFALO, NY- March 14, 2023 – A new research paper was published in Oncotarget's Volume 14 on March 11, 2023, entitled, “Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss.”

Homozygous deletion of methylthioadenosine phosphorylase (MTAP)... continue reading >>

“Selective protection of normal cells may transform therapy of cancer.” 

BUFFALO, NY- March 13, 2023 – A new review paper was published in Oncotarget's Volume 14 on March 11, 2023, entitled, “Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells.”

Cancer therapy is limited by toxicity in normal cells and drug-resistance in cancer cells. In his latest review, Mikhail V. Blagosklonny, M.D., Ph.D., from Roswell Park Comprehensive Cancer Center discusse... continue reading >>

“Overall, this research proposes a new paradigm on how AR-independent PCa can drive tumor traits by exploiting mitochondrial signaling pathways [...]” 

BUFFALO, NY- March 8, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on February 25, 2023, entitled, “Mitochondria engage the integrated stress response to promote tumor growth.”

In this new editorial, researchers Dillon P. Boulton and M. Cecilia Caino from the University of Colorado School of Medicine discussed prostate... continue reading >>

“In the last several years, the Hemoglobin, Albumin, Lymphocyte, Platelet Score (HALP) has emerged in the literature as a new prognostic biomarker [...]” 

BUFFALO, NY- March 6, 2023 – A new review paper was published in Oncotarget's Volume 14 on February 25, 2023, entitled, “What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP’s prognostic ability in different cancer types.”

Since its inception, the Hemoglobin, Albumin, Lymphocyte, Platelet... continue reading >>

“In summary, both articles by Yi et al. emphasized the significance of non-canonical functions of EZH2 during PCa [prostate cancer] development [...]” 

BUFFALO, NY- March 3, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on February 11, 2023, entitled, “Unveiling the non-canonical functions of EZH2 in prostate cancer.”

Prostate cancer (PCa) is ranked as the second leading cause of cancer-related death among American men excluding skin cancer. In this new editorial,... continue reading >>

“The definition of low-risk WNT-pathway medulloblastoma may need to be refined in light of recent clinical data and newer biological information.” 

BUFFALO, NY- February 27, 2023 – A new research perspective was published in Oncotarget's Volume 14 on February 7, 2023, entitled, “WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?”

Novel biological insights have established that medulloblastoma is a heterogenous disease comprising four broad molecular subgroups - WNT,... continue reading >>

“Together, this work highlights the need to investigate different breakpoints of fusion proteins, as they may potentially lack the necessary biological activity required for oncogenesis, ultimately leading to misidentification of presumed oncogenes.” 

BUFFALO, NY- February 23, 2023 – A new research paper was published in Oncotarget's Volume 14 on February 11, 2023, entitled, “Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability... continue reading >>

“Basic functions of ATR classify it in the category of tumor suppressor genes but further studies show that its role is more complex in the context of cancer.” 

BUFFALO, NY- February 21, 2023 – A new research paper was published in Oncotarget's Volume 14 on February 7, 2023, entitled, “The ‘extreme phenotype approach’ applied to male breast cancer allows the identification of rare variants of ATR as potential breast cancer susceptibility alleles.”

In oncogenetics, some patients could be... continue reading >>

“In this study, the ICPI [inflammation-combined prognostic index] was devised as a novel predictive index of prognosis, and its usefulness was clarified.” 

BUFFALO, NY- February 14, 2023 – A new research paper was published in Oncotarget's Volume 14 on January 31, 2023, entitled, “Novel inflammation-combined prognostic index to predict survival outcomes in patients with gastric cancer.”

In vivo inflammatory responses are involved in cancer growth, invasion and metastasis, and the involvement... continue reading >>

“[...] we sought to investigate the mechanism for everolimus-induced inhibition of TP53 HNSCC.” 

BUFFALO, NY- February 9, 2023 – A new research paper was published in Oncotarget's Volume 14 on February 2, 2023, entitled, “Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC).”

TP53 mutant head and neck squamous cell carcinoma (HNSCC) patients exhibit poor clinical outcomes with 50–60%... continue reading >>

“CD200 expression is reported across most cancer types [...]” 

BUFFALO, NY- February 7, 2023 – A new research perspective was published in Oncotarget's Volume 14 on February 4, 2023, entitled, “The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy.”

CD200 is an immunoregulatory cell surface ligand with proven pro-tumorigenic credentials via its ability to suppress CD200 receptor (CD200R)-expressing anti-tumor immune function. This definitive role ... continue reading >>

“The current analysis provides updated results for these lymphoma patients with extended follow-up.” 

BUFFALO, NY- February 1, 2023 – A new research paper was published in Oncotarget's Volume 14 on January 26, 2023, entitled, “Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).”

In this new research paper, researchers Leo I. Gordon, Reem Karmali, Jason B.... continue reading >>

“Immunotherapies, including oncolytic virotherapy, offer novel, targeted approaches to treat brain tumors with increased efficacy and reduced toxicity [5].” 

BUFFALO, NY- January 26, 2023 – A new research perspective was published in Oncotarget's Volume 14 on January 12, 2023, entitled, “Intraventricular immunovirotherapy; a translational step forward.”

In this new perspective, researchers Joshua D. Bernstock, Sarah Blitz, Kyung-Don Kang, and Gregory K. Friedman from Harvard Medical School, Mass... continue reading >>

“The andiroba extract in wounds provides acceleration in healing process, with increase of contraction rate and local re-epithelialization, resulting in the complete closure of wounds [52].” 

BUFFALO, NY- January 24, 2023 – A new research paper was published in Oncotarget's Volume 14 on January 12, 2023, entitled, “The chromatographic constitution of andiroba oil and its healing effects, compared to the LLLT outcomes, in oral mucositis induced in golden Syrian hamsters: a new treatment option.”... continue reading >>

“Taken together, these findings provide a strong rationale for potently and selectively targeting of CD74 in patients with B-NHL [B-cell non-Hodgkin lymphoma].”

BUFFALO, NY- January 17, 2023 – A new research paper was published in Oncotarget's Volume 14 on January 12, 2023, entitled, “Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001.”

Overexpression of CD74, a type II transmembrane glycoprotein involved in MHC class II antigen presentation, has been... continue reading >>

“The goal of the present study was to determine the therapeutic potential of 15d-PMJ2 against melanoma by gaining insight into molecular mechanisms underlying its apoptotic activity.” 

BUFFALO, NY- January 12, 2023 – A new research paper was published in Oncotarget's Volume 13 on December 29, 2022, entitled, “Calcium signaling induced by 15-deoxy-prostamide-J2 promotes cell death by activating PERK, IP3R, and the mitochondrial permeability transition pore.”

Melanoma is the deadliest form of... continue reading >>

“In this study, we aimed to analyze our experience with patients suffering from Sars-CoV-2 infection while receiving treatment for metastatic melanoma.” 

BUFFALO, NY- January 11, 2023 – A new research paper was published in Oncotarget's Volume 13 on December 29, 2022, entitled, “Impact of Covid-19 on the management of patients with metastatic melanoma.”

The Covid-19 pandemic created new uncertainties in the management of metastatic melanoma patients. In particular, the impact of... continue reading >>

“One of the impediments to successful cancer therapy is the heterogeneity and cellular plasticity of the tumor and TME [22, 23].” 

BUFFALO, NY- January 5, 2023 – A new research paper was published in Oncotarget's Volume 13 on December 20, 2022, entitled, “Resistance of MMTV-NeuT/ATTAC mice to anti-PD-1 immune checkpoint therapy is associated with macrophage infiltration and Wnt pathway expression.”

One of the central challenges for cancer therapy is the identification of factors in the tumor... continue reading >>